Evidence map›Paper›PMID 28784174›Full record

ArticleJournal of ovarian research2017

Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.

Rosie T Jiang, Anna Yemelyanova, Deyin Xing, Ravi K Anchoori, Jun Hamazaki, Shigeo Murata, Jeffrey D Seidman, Tian-Li Wang, Richard B S Roden

Open access · goldAbstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in Journal of ovarian research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it

0cells of the map it votes in

11citing papers in PubMed

0.9field-weighted citation impact, top 26% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

NMR-Guided Studies to Establish the Binding Interaction between a Peptoid and Protein.Journal of the American Chemical Society · 2025
Article
Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor.PloS one · 2023
Article
GMEB2 Promotes the Growth of Colorectal Cancer by Activating ADRM1 Transcription and NF-κB Signalling and Is Positively Regulated by the mCancers · 2022
Article
Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.PloS one · 2021
Article
Mechanistic Studies of the Multiple Myeloma and Melanoma Cell-Selective Toxicity of the Rpn13-Binding Peptoid KDT-11.Cell chemical biology · 2020
Article
Unstructured Biology of Proteins from Ubiquitin-Proteasome System: Roles in Cancer and Neurodegenerative Diseases.Biomolecules · 2020
Article
Drug Development Targeting the Ubiquitin-Proteasome System (UPS) for the Treatment of Human Cancers.Cancers · 2020
Review
Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties.PloS one · 2020
Article
Proteomic and Transcriptomic Profiling Identifies Early Developmentally Regulated Proteins inCells · 2019
Article
Small-Molecule Inhibitors of the Proteasome's Regulatory Particle.Chembiochem : a European journal of chemical biology · 2019
Review
Ubiquitin Receptor RPN13 Mediates the Inhibitory Interaction of Diphenyldihaloketones CLEFMA and EF24 With the 26S Proteasome.Frontiers in chemistry · 2018
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Rosie T JiangDepartment of Pathology, The Johns Hopkins University, Baltimore, MD, 21231, USA.

Anna YemelyanovaDepartment of Pathology, The Johns Hopkins University, Baltimore, MD, 21231, USA.

Deyin XingDepartment of Pathology, The Johns Hopkins University, Baltimore, MD, 21231, USA.

Ravi K AnchooriDepartment of Oncology, The Johns Hopkins University, Baltimore, MD, 21231, USA.

Jun HamazakiLaboratory of Protein Metabolism, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Shigeo MurataLaboratory of Protein Metabolism, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Jeffrey D SeidmanDivision of Molecular Genetics and Pathology, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD, 20993, USA.

Tian-Li WangDivision of Gynecologic Pathology, The Johns Hopkins University, Baltimore, MD, 21231, USA.

Richard B S RodenDepartment of Pathology, The Johns Hopkins University, Baltimore, MD, 21231, USA. roden@jhmi.edu.ORCID http://orcid.org/0000-0002-2506-0195

Johns Hopkins University · USThe University of Tokyo · JPCenter for Devices and Radiological Health · US

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI Richard Bruce Roden · 2003 to 2026

$53.5M

NCI NIH HHS P50 CA098252

6 · The paper itself

Abstract

backgroundOvarian carcinoma is highly dependent on the ubiquitin proteasome system (UPS), but its clinical response to treatment with the proteasome inhibitor bortezomib has been disappointing. This has driven exploration of alternate approaches to target the UPS in ovarian cancer. Recently, proteasome inhibitors targeting the 19S regulatory particle-associated RPN13 protein have been described, such as RA190. RPN13, which is encoded by ADRM1, facilitates the recognition by the proteasome of its polyubiquinated substrates. Inhibition of RPN13 produces a rapid, toxic accumulation of polyubiquitinated proteins in ovarian and other cancer cells, triggering apoptosis. Here, we sought to determine if RPN13 is available as a target in precursors of ovarian/fallopian tube cancer as well as all advanced cases, and the impact of increased ADRM1 gene copy number on sensitivity of ovarian cancer to RA190.

methodsADRM1 mRNA was quantified by RNAscope in situ hybridization and RPN13 protein detected by immunohistochemistry in high grade serous carcinoma (HGSC) of the ovary and serous tubal intraepithelial carcinoma (STIC). Amplification of ADRM1 and sensitivity to RA190 were determined in ovarian cancer cell lines.

resultsHere, we demonstrate that expression of ADRM1mRNA is significantly elevated in STIC and HGSC as compared to normal fallopian tube epithelium. ADRM1 mRNA and RPN13 were ubiquitously and robustly expressed in ovarian carcinoma tissue and cell lines. No correlation was found between ADRM1 amplification and sensitivity of ovarian cancer cell lines to RA190, but all were susceptible.

conclusionsRPN13 can potentially be targeted by RA190 in both in situ and metastatic ovarian carcinoma. Ovarian cancer cell lines are sensitive to RA190 regardless of whether the ADRM1 gene is amplified.

Indexed as

AgedBenzylidene CompoundsCell Line, TumorCystadenocarcinoma, SerousFallopian Tube NeoplasmsFemaleHumansIntracellular Signaling Peptides and ProteinsMembrane GlycoproteinsMiddle AgedOvarian NeoplasmsProteasome InhibitorsRNA, MessengerTumor Suppressor Protein p53ADRM1 protein, humanBenzylidene CompoundsIntracellular Signaling Peptides and ProteinsMembrane GlycoproteinsProteasome InhibitorsRA190RNA, MessengerTP53 protein, humanTumor Suppressor Protein p53ADRM1Ovarian/fallopian tube cancerProteasome inhibitorRPN13STIC

Identifiers

PMID28784174

DOI10.1186/s13048-017-0347-y

PMCPMC5547474

OpenAlexW2742961007

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.